Black Diamond Therapeutics
BDTX
76 hedge funds and large institutions have $107M invested in Black Diamond Therapeutics in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 13 closing their positions.
541% more call options, than puts
Call options by funds: $186K | Put options by funds: $29K
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
4% more funds holding
Funds holding: 73 → 76 (+3)
1.71% more ownership
Funds ownership: 72.11% → 73.82% (+1.7%)
0% more capital invested
Capital invested by funds: $107M → $107M (+$332K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$4.16M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.29M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.63M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$938K |
| 5 |
Two Sigma Investments
New York
|
+$674K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.2M |
| 2 |
DM
Deerfield Management
New York
|
-$2.67M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$1.82M |
| 4 |
EP
Eversept Partners
New York
|
-$968K |
| 5 |
JP Morgan Chase
New York
|
-$671K |
BDTX Hedge Fund Activity: Q4 2023 in Review
76 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2023, worth a combined $107M — up 0.31% from $107M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BDTX positions and 13 closed out — a net gain of 5 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $4.16M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.2M sold.
- 76 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2023, up from 73 in Q3 2023.
- Funds reported $107M of Black Diamond Therapeutics stock for Q4 2023, up 0.31% quarter-over-quarter.
- 18 funds opened new Black Diamond Therapeutics positions in Q4 2023 and 13 closed out, a net change of +5 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2023 was T. Rowe Price Investment Management, an estimated $4.16M added.
- The largest Black Diamond Therapeutics seller in Q4 2023 was Point72 Asset Management, an estimated $3.2M sold.
Based on aggregated 13F filings for Q4 2023.